Please use the search feature, return to the home page, or visit one of the following:

SORRY, WE COULDN’T FIND THAT PAGE

The page you are searching for does not exist.

Either it has moved, or the link is broken.

ERROR CODE: 404

DALLAS, Sept. 3, 2026 /PRNewswire/ -- Southwest Airlines Co. (NYSE: LUV) Executive Vice President & Chief Financial Officer Tom Doxey will participate in a fireside chat at the Morgan Stanley 14th Annual Laguna Conference on September 16 at 12:20 pm PST. Morgan Stanley will be webcasting the audio presentation live. A link to the webcast will be made available via the Investor Relations page on the Southwest website. Details of the audio webcast are as follows:

To access the live audio webcast and subsequent replay, click on the link above, or go to www.southwest.com and click on "Investor Relations" under the "About Southwest" menu at the bottom of the page. The audio webcast can be found on the homepage or by clicking "Calendar" under the "News & Events" header.

SOURCE Southwest Airlines Co.

Share this article

Digital Collectibles Platform Expands Its Loyalty Program with Additional Rewards for Collectors

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Trove, a digital collectibles app built to reconnect people with the feeling of collecting as a kid, has introduced Collection Dividends, a first of its kind feature that rewards collectors for building collections on Trove.

With Collection Dividends, collectors will earn a minimum of 2% annually on the value of their collection, calculated and paid monthly in Trove Cash. Available to all Trove collectors, without having to stake their assets, lock up or turn over ownership, the benefit is designed to recognize collections as assets with value beyond the initial transaction, and is a first of its kind benefit not currently available on any other major collectibles platform.

While the industry has both innovated and celebrated the transaction, Trove is committed to delivering the same joy across the entire collector experience. Three pillars that make up Trove's commitment to the collector experience: Curating the most desirable cards; 100% and forever buyback options to always provide liquidity to the collector; and now, programs that reward the collector for building long term value on Trove.

"The collectibles industry has spent a tremendous amount of energy making the purchase experience more exciting, but has completely ignored the collector experience," said Michael Katz, co-founder and CEO of Trove. "While everyone claims to be for collectors by collectors, none of their investments actually deliver on that. This is just one more step in our commitment to deliver more value to collectors."

Building for Collectors, Not Just Transactions

Founded in 2025, Trove combines the thrill of opening digital packs with ownership of real, authenticated cards across major sports, Pokémon and One Piece, securely stored in the PSA Vault. After purchasing a pack on Trove, collectors can choose to build a collection on Trove, have the physical cards shipped directly to them, or immediately sell back to Trove for 100% of fair market value.

Trove is also built around transparency and trust, with transparent outcomes, PSA verified inventory, provable fairness that allows collectors to verify outcomes, and flexible sellback options. Collection Dividends is the latest step in Trove's broader vision to build new value and utility around collectible ownership while continually reinvesting in the collector experience.

The founding team is made up of lifelong collectors and bring more than two decades of experience building technology companies at the intersection of data, consumer behavior and emerging technology.

Learn more at https://trove.xyz/

About Trove

Trove is a collectibles company building a new way for people to discover and collect what they love. The platform combines the excitement of digital pack opening with ownership of real, authenticated collectibles, offering curated inventory, transparent odds, provable fairness, collection analytics and liquidity. Trove currently offers cards across major sports, Pokémon and One Piece, with cards securely stored in its vault and available for physical delivery.

Media Contact:

Dan Sabreen

Trove PR

dsabreen@gmail.com 

SOURCE Trove, Inc

Share this article

Spoločnosť TCL na veľtrhu IFA 2026 demonštruje svoje rastúce ambície a predstavuje nový rad smartfónov P80

BERLÍN, 3. septembra 2026 /PRNewswire/ -- TCL, globálny líder v oblasti spotrebnej elektroniky a zobrazovacích technológií, dnes na veľtrhu IFA 2026 predstavil rad smartfónov TCL P80. Nový rad, ktorý zahŕňa modely TCL P80 Ultra, TCL P80 Pro a TCL P80, reaguje na rôzne priority smartfónov tromi jasne definovanými úrovňami zážitku, ktoré zahŕňajú mobilné fotografovanie, pohodlie displeja, každodenný výkon a štíhly dizajn.

V nadväznosti na skúsenosti s displejom NXTPAPER AMOLED, ktorý bol predstavený na svetovom veľtrhu mobilných technológií a konektivity MWC 2026, spoločnosť TCL teraz prináša túto technológiu do modelov TCL P80 Ultra a TCL P80 Pro. Kombináciou živých farieb a hlbokého kontrastu AMOLED displeja s technológiami NXTPAPER navrhnutými na zníženie odleskov a vystavenia modrému svetlu podporujú obe zariadenia pohodlnejšie sledovanie počas celého dňa. Tento zážitok, vyvinutý vďaka špecializovaným mobilným a zobrazovacím funkciám spoločnosti TCL, je doplnený pokročilou fotografiou, silným výkonom a spoľahlivou výdržou batérie, čím vytvára ešte komplexnejšiu ponuku prémiových mobilných zariadení.

Model TCL P80 Ultra je doteraz najlepší model od spoločnosti TCL a na čele celého radu stojí vďaka špeciálnemu 50 MP periskopickému teleobjektívu s trojnásobným priblížením, ktorý používateľom poskytuje väčšiu slobodu pri komponovaní záberov vzdialených objektov, portrétov a pouličných scén. Model TCL P80 Pro ponúka vyváženú kombináciu špičkového 1,5K NXTPAPER AMOLED displeja, všestranného zobrazovania, batérie s kapacitou 5 800 mAh[1] a úložiska s veľkosťou až 512 GB[2]. Rad dopĺňa model TCL P80, ktorý prichádza s tenkým profilom a veľkým 1,5K AMOLED displejom pre používateľov hľadajúcich cenovo dostupný smartfón zameraný na najdôležitejšie funkcie na každý deň.

„Dnešný smartfón by mal robiť viac než len udržiavať ľudí online. Mal by im pomáhať bez námahy prepínať medzi zachytávaním vzdialených okamihov, čítaním počas dochádzania do práce, zvládaním pracovných úloh a užívaním si zábavy, a zároveň im uľahčiť vypnutie, keď si to želajú," povedal Stefan Streit, riaditeľ marketingu spoločnosti TCL Europe. „S modelom P80 Ultra predstavujeme doteraz najpokročilejší smartfón od spoločnosti TCL, ktorý spája našu najnovšiu technológiu displeja NXTPAPER AMOLED, pokročilé fotografie, silný výkon a spoľahlivú výdrž batérie v jednom kompletnom prémiovom zážitku. V rámci širšieho radu P80 napĺňame našu ambíciu priniesť viac prémiových mobilných skúseností a praktickej hodnoty väčšiemu počtu ľudí a zároveň dbať na ich digitálnu pohodu."

TCL P80 Ultra: priblížte si vzdialené momenty

Model TCL P80 Ultra je určený pre ľudí, ktorí chcú viac slobody pri zachytávaní vzdialených okamihov. Jeho vynikajúcou funkciou je 50 MP periskopický teleobjektív s trojnásobným priblížením s optickou a elektronickou stabilizáciou obrazu (OIS + EIS), ktorá uľahčuje približovanie vzdialených objektov a zároveň zachováva ostrosť a stabilitu obrazu. Systém fotoaparátov obsahuje aj 50 MP hlavný fotoaparát s 1/1,56-palcovým snímačom a optickou stabilizáciou obrazu (OIS) + elektronickou stabilizáciou obrazu (EIS), 8 MP ultraširokouhlý fotoaparát s automatickým zaostrovaním pre širšie scény a 32 MP predný fotoaparát pre jasné selfie a videohovory.

Celý rad P80 čerpá z 27-ročných skúseností spoločnosti TCL v oblasti mobilnej komunikácie, posilňuje jej pozíciu profesionálnej značky smartfónov a zároveň sprístupňuje prémiové mobilné technológie väčšiemu počtu spotrebiteľov.

Konfigurácie produktov, farby, príslušenstvo, ceny a dostupnosť sa môžu líšiť v závislosti od trhu a predajného kanála.

O spoločnosti TCL Mobile

Spoločnosť TCL Mobile sa špecializuje na výskum, vývoj a výrobu smartfónov, tabletov a pripojených zariadení. S cieľom poskytnúť 5G pre všetkých pomáha spoločnosť TCL Mobile svojim zákazníkom „inšpirovať k úspechu" prostredníctvom špičkových technológií a riešení.

Viac informácií o mobilných zariadeniach TCL nájdete na adrese: https://www.tcl.com/global/en/mobile

[1] Uvedená kapacita batérie je typická hodnota. Skutočná výdrž a výkon batérie sa môžu líšiť v závislosti od nastavení zariadenia, podmienok siete, spôsobov používania a ďalších faktorov.

[2] Konfigurácie pamäte, možnosti úložiska, farby, funkcie a dostupnosť produktu sa môžu líšiť v závislosti od krajiny, trhu a predajného kanála.

Share this article

LOS ANGELES and ATHENS, Greece, Sept. 3, 2026 /PRNewswire/ -- ALS Network and the Hellenic ALS Association today announced an international collaboration surrounding an extraordinary endurance expedition connecting two countries and two ALS communities through a shared commitment to people and families impacted by amyotrophic lateral sclerosis (ALS).

This October 5-12, longtime ALS Network supporter Tom Horton will embark on an ambitious paddling expedition through the Greek Islands in honor of his late mother, whose Greek heritage inspired a lifelong appreciation for the country's history, culture and people. Joined by nine family members and friends, the deeply personal journey will carry an equally important purpose: raising awareness of ALS and generating support for individuals and families impacted by the disease in both the United States and Greece.

"Tom's journey is about so much more than the miles he will travel," said Sheri Strahl, MPH, MBA, president and CEO, ALS Network. "It's a deeply personal tribute rooted in family, heritage, and remembrance. We're proud to join with Tom and the Hellenic ALS Association to bring our communities together, raise greater awareness of ALS, and remind people of the powerful impact we can have through collaboration."

ALS, also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells responsible for controlling voluntary muscle movement. While ALS affects people and families around the world, access to resources, specialized care and support can vary significantly.

ALS Network and the Hellenic ALS Association share a commitment to improving the lives of people living with ALS while helping build greater awareness and momentum toward a world without the disease.

"We are deeply honored to join ALS Network in this collaboration," said Aspa Karampela, president of the Hellenic ALS Association. "Tom's expedition is a powerful reminder that compassion and determination know no borders. Together, we hope this journey inspires people in Greece and the United States to take action, raise awareness and create new opportunities for people living with ALS and their families."

As part of the collaboration, the Hellenic ALS Association will lead fundraising efforts in Greece to support its work serving people living with ALS throughout the country. In the United States, donations made through ALS Network's Greece expedition campaign will support ALS Network's mission.

Throughout the expedition, both organizations will share photographs, videos and updates from Horton's journey, providing supporters in both countries an opportunity to follow his progress.

The campaign will also highlight the individuals and families whose experiences provide the greater purpose behind the expedition.

For Horton, the journey brings together his mother's legacy, his connection to Greece and his longstanding commitment to the ALS community.

For the two organizations, it represents a simple but powerful belief: ALS knows no borders and neither does hope.

To follow Tom's journey or support the campaign, visit paddlingtocureals.org.

About ALS Network

The ALS Network partners with the ALS community to drive the global discovery of prevention strategies, treatments, and cures for ALS; provide access to quality care and connection; and promote initiatives and legislation to improve health outcomes. For more information about ALS and the ALS Network, visit alsnetwork.org or email info@alsnetwork.org. You can find the ALS Network on social media at @yourALSnetwork.

About the Hellenic ALS Association

The Hellenic ALS Association is the national patient association representing and supporting people living with Amyotrophic Lateral Sclerosis (ALS) and motor neuron diseases (MND), and their families in Greece The Association works to improve the quality of life, care, and support available to people living with ALS and their families across Greece. Its activities include online support groups, dedicated patient and caregiver communities, access to reliable information and resources, advocacy for improved healthcare and social support, and awareness and educational initiatives with healthcare professionals and clinical centers throughout the country. Visit alshellas.gr for details.

Media Contact

Eric Beikmann

ebeikmann@alsnetwork.org

SOURCE ALS Network

Share this article

Roman Stone Selected to Supply EZ-KEY™ Precast Duct Bank System for Major Data Center Project

CANTON, Ohio, Sept. 3, 2026 /PRNewswire/ -- Roman Stone, a leading manufacturer of engineered precast concrete infrastructure solutions, announced it has been selected to supply its patented EZ-KEY™ Precast Duct Bank System for a major hyperscale data center project in Canton, Ohio.

The project represents another milestone in Roman Stone's continued national expansion as the company delivers innovative precast infrastructure solutions to critical infrastructure projects throughout the United States. Through nationwide logistics and mobile manufacturing capabilities, Roman Stone supports customers from coast to coast, helping contractors improve quality, reduce transportation costs, accelerate schedules, and improve construction efficiency. Roman Stone's mobile manufacturing operations produce its precast concrete products at or near the project site, utilizing a workforce from the nearby communities.

As investment in data centers, AI infrastructure, and cloud computing continues to increase nationwide, demand for dependable underground electrical infrastructure has never been greater. Roman Stone's EZ-KEY™ system was specifically engineered to simplify duct bank installation while reducing labor requirements, improving consistency, and helping projects stay on schedule.

Unlike traditional cast-in-place construction, EZ-KEY™ arrives at the jobsite as a factory-produced precast system ready for installation. Each 10-foot section can be installed in under two minutes using Roman Stone's innovative alignment cones and proprietary Zip Pin connection system, allowing contractors to complete installations faster while maintaining precise alignment and quality. The modular "Lego-like" design reduces field labor, minimizes weather-related delays, and delivers consistent results on every installation.

"This data center project, which we believe will be the first of many, reflects the growing demand for innovative infrastructure solutions that improve productivity while maintaining exceptional quality," said Daniel Murray, President and CEO of Roman Stone. "We're proud to support customers across the country with engineered precast systems that help keep critical infrastructure projects moving."

Roman Stone delivers engineered precast solutions nationwide through strategic logistics, project management, and mobile manufacturing capabilities. The EZ-KEY™ system supports critical infrastructure applications including data centers, substations, utility corridors, transportation, and telecommunications projects by providing factory-produced components that improve installation quality, reduce labor, and accelerate project schedules.

Founded in 1903, Roman Stone has more than 120 years of experience manufacturing engineered precast concrete products. Today, the company continues to advance innovative technologies that help customers build critical infrastructure more efficiently while maintaining the highest standards of quality and performance.

For more information about Roman Stone and the EZ-KEY™ Precast Duct Bank System, visit www.romanstoneco.com.

Media Contact:

Amanda Cain

631-357-6126

421888@email4pr.com 

SOURCE Roman Stone Construction Co.

Share this article

The Center for Responsible Food Business uncovered how lobbyists for Chinese-owned Smithfield Foods failed to properly disclose foreign interests for years.

WASHINGTON, Sept. 3, 2026 /PRNewswire/ -- Following a federal complaint filed August 3 by the Center for Responsible Food Business (CRFB) with the Secretary of the Senate and the Clerk of the House, Smithfield Foods's lobbying firm, Greenberg Traurig, LLP, has quietly amended its most recent federal lobbying report to disclose that WH Group (萬洲國際) — the China-based company that owns 86.9% of Smithfield — has an interest in Smithfield's lobbying on the Farm Bill and on foreign ownership of U.S. agricultural land.

Greenberg Traurig's original second-quarter report, filed July 20, 2026, answered "None" on Line 19, where federal law requires lobbyists to disclose any foreign entity's interest in the specific issues they lobbied. Those issues included "Farm Bill reauthorization" and "issues related to foreign ownership of agricultural land," and the report covers $120,000 in lobbying directed at the U.S. House, the U.S. Senate, and the Department of the Treasury.

On August 18, fifteen days after CRFB's complaint, the firm submitted an amended report to name Smithfield's owner — WH Group of Kowloon, Hong Kong — as a foreign entity with an interest in both lobbying areas.

Smithfield's July filing was no isolated lapse; it was the fifteenth consecutive quarterly report since the beginning of 2023 to report lobbying on foreign land ownership legislation for Smithfield while denying that any foreign entity had an interest. Fourteen of the fifteen reports remain uncorrected.

"It should not take a watchdog group's complaint to compel a major global corporation to comply with federal disclosure laws about foreign lobbying interests," said Taylor Warren, President of the Center for Responsible Food Business. "Smithfield's years-long omission and sudden about-face suggest it never intended to admit that its lobbyists really represent China. And why would it? It serves Smithfield to masquerade as an America-first company when pushing for policies that benefit its Chinese owner."

With the corrected filing now on the record, no member of Congress can claim not to know whose interests stand behind Smithfield's money and its lobbying agenda.

Copies of the lobbying filings and CRFB's complaint are available on request.

Media Contact

Taylor Warren: media@responsiblefoodbusiness.org

About the Center for Responsible Food Business

The Center for Responsible Food Business is a nonprofit dedicated to promoting corporate social responsibility to build a better food system. Through industry engagement, research, and consumer education efforts, the Center works to advance practices that benefit all stakeholders from the farm to the dinner table.

SOURCE Center for Responsible Food Business

Share this article

Pulnovo Medical gibt Ergebnisse der PADN-HF-PH-Studie auf dem ESC-Kongress 2026 bekannt; diese werden gleichzeitig im „New England Journal of Medicine" (NEJM) veröffentlicht

Die klinischen Ergebnisse von 264 Patientinnen und Patienten mit pulmonaler Hypertonie und linksventrikulärer Hypertrophie (PH-LHD) zeigen eine Verringerung des Risikos einer klinischen Verschlechterung um 51 %, einen Rückgang der wiederkehrenden klinischen Ereignisse um 35,5 % sowie anhaltende, damit einhergehende Verbesserungen der funktionellen Leistungsfähigkeit, was die vielschichtigen therapeutischen Vorteile des Pulmonary Artery Denervation (PADN)-Systems untermauert.

SHANGHAI, 3. September 2026 /PRNewswire/ -- Pulnovo Medical gab bekannt, dass bahnbrechende Ergebnisse der PADN-HF-PH-Studie offiziell im Rahmen der „Hot Line 6"-Sitzung auf dem Kongress der Europäischen Gesellschaft für Kardiologie (European Society of Cardiology, ESC) 2026 vorgestellt und gleichzeitig im The New England Journal of Medicine (NEJM) veröffentlicht werden. In dem Artikel im NEJM werden Professor Shao-Liang Chen vom Nanjing First Hospital, Akademiemitglied Yaling Han vom General Hospital of Northern Theater Command und Professor Gregg W. Stone vom Mount Sinai Hospital als gemeinsame korrespondierende Autoren genannt. Die mit großer Spannung erwartete Veröffentlichung stellt einen Meilenstein für kardiovaskuläre Interventionen dar und liefert hochwertige klinische Erkenntnisse, die den Weg für die nächste Generation globaler, evidenzbasierter Therapiestrategien zur Behandlung von Herzinsuffizienz ebnen.

Die PADN-HF-PH-Studie ist eine multizentrische, randomisierte, kontrollierte klinische Studie mit 264 Patientinnen und Patienten unter der Leitung von Akademiemitglied Yaling Han vom General Hospital of Northern Theater Command. Die Studie diente der Bewertung der Sicherheit und der klinischen Wirksamkeit einer Ergänzung der leitliniengerechten medikamentösen Therapie (Guideline-Directed Medical Therapy, GDMT) durch eine pulmonalarterielle Denervation (Pulmonary Artery Denervation, PADN) bei Patientinnen und Patienten mit pulmonaler Hypertonie im Zusammenhang mit einer Linksherzkrankheit (PH-LHD).

Bei Patientinnen und Patienten mit PH-LHD verstärken sich pulmonale Hypertonie und linksseitige Herzerkrankung gegenseitig, was zu einer höheren Symptombelastung und schlechten klinischen Ergebnissen führt. Derzeit konzentrieren sich die Behandlungen bei PH-LHD in erster Linie auf die zugrunde liegende Erkrankung der linken Herzkammer. Zwar verbessert die GDMT die Gesamtprognose für Patientinnen und Patienten mit Herzinsuffizienz, doch besteht nach wie vor ein gravierender Mangel an zugelassenen, spezifischen Therapien, die direkt auf die pulmonale Hypertonie abzielen.

Zusammenfassung der wichtigsten Ergebnisse:

- 51 % geringeres Risiko einer klinischen Verschlechterung: Während einer medianen Nachbeobachtungszeit von 338 Tagen betrug die nach Kaplan-Meier geschätzte 2-Jahres-Inzidenz einer klinischen Verschlechterung in der PADN-plus-GDMT-Gruppe 25,7 %, verglichen mit 51,5 % in der Gruppe, die ausschließlich gemäß GDMT behandelt wurde.

- Äußerst aussagekräftiges Ergebnis des primären Endpunkts: Dies entspricht einer Verringerung des Risikos einer klinischen Verschlechterung um 51 % (Hazard Ratio: 0,49; 95 %-Konfidenzintervall: 0,30 bis 0,82; P = 0,006). Die Wirkung hielt über den gesamten Nachbeobachtungszeitraum an, was für diese chronische, fortschreitende Erkrankung klinisch relevant ist.

- Umfassende Verbesserung der kombinierten Endpunkte: Der primäre Endpunkt war ein streng definierter Zusammenschluss von Ereignissen einer klinischen Verschlechterung, definiert als Tod, Herz- oder Lungentransplantation, Krankenhausaufenthalt wegen Herzinsuffizienz, ambulante Verschlechterung der Herzinsuffizienz, die zu einer intravenösen Diurese führte, oder eine signifikante Verkürzung der Strecke beim 6-Minuten-Gehtest. Diese ganzheitliche Beurteilung spiegelt die tatsächlichen Veränderungen im langfristigen Krankheitsverlauf von Patrientinnen und Patienten wider.

- Rückgang der wiederkehrenden klinischen Ereignisse: Bei Erst- und wiederkehrenden Ereignissen einer klinischen Verschlechterung betrug die annualisierte Rate in der PADN-Gruppe 36,3 pro 100 Patientenjahre gegenüber 56,3 pro 100 Patientenjahre in der GDMT-Gruppe.

- Reduzierung der Gesamtkrankheitslast: Dies entspricht einem Rückgang der annualisierten Rezidivrate um 35,5 % (Hazard-Ratio 0,59; 95 %-Konfidenzintervall: 0,39 bis 0,89), was darauf hindeutet, dass PADN die gesamte Krankheitslast verändert und nicht lediglich das erste Ereignis hinauszögert.

- Schutz vor funktionellem Verfall (6MWD): PADN führte zu einer Verbesserung der Funktionsfähigkeit und des Gesundheitszustands. Nach zwölf Monaten konnten die Patientinnen und Patienten eine Nettoverbesserung beim 6-Minuten-Gehtest um 24,8 Meter erzielen. Insbesondere wurde das Risiko, einen Rückgang der 6-Minuten-Gehstrecke um 10 % oder mehr zu verzeichnen, um 63 % gesenkt (Hazard Ratio: 0,37; 95 %-Konfidenzintervall: 0,15 bis 0,92).

- Übereinstimmende Verbesserungen der Lebensqualität (KCCQ) und der Biomarker (NT-proBNP): Die übereinstimmenden Verbesserungen der körperlichen Leistungsfähigkeit, des Gesundheitszustands und der Ventrikelfunktion sorgten für eine hohe interne Konsistenz. PADN führte zu einer Verbesserung des Gesundheitszustands, gemessen anhand des Gesamtsummen-Scores des Kansas City Cardiomyopathy Questionnaire (KCCQ-OSS). Sechs Monate nach dem Eingriff wiesen die Patientinnen und Patienten im Vergleich zu den Patientinnen und Patienten, die ausschließlich eine GDMT erhielten, einen stärkeren Rückgang der Natriuretischen Peptidwerte (NT-proBNP) gegenüber den Ausgangswerten auf.

- Günstiges Sicherheitsprofil: Das Verfahren erwies sich als sicher: Hämatome an der Einstichstelle traten nur bei zwei Patienten in der PADN-Gruppe und bei einem Patienten in der GDMT-Gruppe auf; sonstige Komplikationen im Zusammenhang mit dem Eingriff traten nicht auf.

Die soliden, vielschichtigen Erkenntnisse aus der PADN-HF-PH-Studie werden voraussichtlich ein neues klinisches Paradigma etablieren. Durch die umfassende Verringerung der klinischen Verschlechterung, die Senkung der Rezidivraten sowie die Verbesserung des Funktionsstatus und wichtiger Biomarker liefert die Studie entscheidende neue Erkenntnisse für die Behandlung von Patientinnen und Patienten mit PH-LHD.

Informationen zur pulmonalarteriellen Denervation

Die von Pulnovo entwickelte pulmonalarterielle Denervation (Pulmonary Artery Denervation, PADN) ist eine minimalinvasive Therapie, die darauf abzielt, die überhöhte Aktivität des sympathischen Nervensystems zu modulieren, die zur Veränderung der pulmonalen Gefäße und zum Fortschreiten kardiopulmonaler Erkrankungen beiträgt.

Die Therapie wurde in mehreren internationalen klinischen Leitlinien anerkannt, unter anderem durch ihre Aufnahme als experimentelle interventionelle Therapie in die Leitlinien der Europäischen Gesellschaft für Kardiologie (European Society of Cardiology, ESC) und der Europäischen Gesellschaft für Atemwegserkrankungen (European Respiratory Society, ERS) aus dem Jahr 2022 zur Diagnose und Behandlung der pulmonalen Hypertonie, und wurde bislang in insgesamt sieben klinischen Leitlinien erwähnt.

Die klinische Erprobung des PADN-Verfahrens wird derzeit bei verschiedenen Subtypen der pulmonalen Hypertonie fortgesetzt. Aufbauend auf den behördlichen Zulassungen in zwölf Ländern/Regionen und der klinischen Erfahrung aus rund 1.500 Eingriffen bei Patientinnen und Patienten mit pulmonaler Hypertonie der WHO-Gruppe 1. Pulnovo Medical weitet seine klinische Untersuchung der Therapie auf Patientinnen und Patienten mit pulmonaler Hypertonie der WHO-Gruppe 2 im Zusammenhang mit einer Linksherzkrankheit (PH-LHD) aus, um den erheblichen ungedeckten klinischen Bedarf dieser breiteren Patientengruppe zu decken.

Informationen zu Pulnovo Medical

Pulnovo Medical ist ein innovatives Medizintechnikunternehmen, das sich der Entwicklung interventioneller Therapien für pulmonale Hypertonie und Herzinsuffizienz widmet. Ausgerichtet auf klinischen Nutzen entwickelt das Unternehmen bahnbrechende Lösungen auf Grundlage seiner firmeneigenen Technologieplattform mit einem Schwerpunkt auf globaler klinischer Entwicklung und Vermarktung, um die Behandlungsergebnisse von Patientinnen und Patienten weltweit zu verbessern. Weitere Informationen finden Sie auf www.pulnovomed.com.

Share this article

SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 55,867 shares of GRAIL's common stock to 59 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over an approximately four year period, with 25% of the award vesting Aug. 31, 2027, and on each one year anniversary of those respective dates thereafter, subject to continued employment with GRAIL (or any successor to or subsidiary of the Company) through the vesting dates.

About GRAIL

GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Sunnyvale, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.

For more information, visit grail.com.

SOURCE GRAIL, Inc.

Share this article

Peckham Industries, Inc. Announces Senior Leadership Change

BREWSTER, N.Y., Sept. 3, 2026 /PRNewswire/ -- Peckham Industries, Inc. (the "Company") today announced that John R. Peckham has been appointed interim Chief Executive Officer, effective immediately. He replaces Damian J. Murphy, who is no longer associated with the Company.

Mr. Peckham returns as Chief Executive Officer, a position he held from 1993 to 2021 before assuming his role as Chairman of the Board. He has worked for the Company for nearly 50 years and has been integral in shaping the culture and standards that define The Peckham Way, as well as in establishing and supporting the Company's strategic growth plan. He will provide continuity and stability as the Company transitions to new leadership, and will continue to serve on the Board of Directors during the interim period.

"Peckham has been a family-owned business for more than a century, and in that time our word has always been our bond," said John R. Peckham. "That standard governs how we work with our members, our customers, and our partners, and it does not change when leadership changes. We remain committed to safety, integrity, dedication, and transparency, to our Family by Choice culture, and to operating best-in-class in a safe and sustainable manner."

The Company does not anticipate any change to its day-to-day operations, customer commitments, or long-term growth strategy. Leadership will remain in direct contact with customers and partners throughout the transition.

For media inquiries, please contact: press@peckham.com

Peckham Industries is a family company established in 1924. The Company headquarters are in Brewster, NY. The Company operates in New York, Connecticut, Massachusetts, Rhode Island, Vermont and New Hampshire.

SOURCE Peckham Industries

Share this article